3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Lung Neoplasms
18
Breast Neoplasms
11
Ovarian Neoplasms
10
Uterine Cervical Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Fallopian Tube Neoplasms
5
Adenocarcinoma of Lung
5
Neoplasms
4
Neoplasm Metastasis
4
Central Nervous System Neoplasms
4
Esophageal Neoplasms
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Retinoblastoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Inflammatory Breast Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Brain Neoplasms
2
Adenocarcinoma, Bronchiolo-Alveolar
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thoracic Neoplasms
1
Salivary Gland Neoplasms
1
Interventions
vandetanib
1
trametinib
1
fosbretabulin
1
dabrafenib
1
combretastatin
1
ceritinib
1
Paclitaxel
1
Docetaxel
1
Carboplatin
1
Adalimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Thyroid Carcinoma, Anaplastic
×
Carboplatin
×
Clear all
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn